Condition 1: Polycystic ovarian syndrome. Condition 2: Vitamin D deficiency, unspecified. Polycystic ovarian syndrome Vitamin D deficiency, unspecified
Conditions
Interventions
Intervention 1: Intervention group1: Probiotic group - Vitamin D 50,000 IU vitamin D3 every two weeks along with one capsule of Lactofem containing Lactobacillus rhamnosus, Lactobacillus fermentum, La
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Age range 18-40 years A resident of Urmia Diagnosis of PCOS based on the Rotterdam indices. The Rotterdam criteria include having more than two of these symptoms: oligo/no ovulation, hyperandrogenism (symptoms such as hirsutism, acne, male pattern alopecia, increased free testosterone) and polycystic ovaries based on ultrasound (having 12 or more The follicle in each ovary is 2-9 mm in size People with blood levels of 25 hydroxyvitamin D less than 30 ng/ml
Exclusion criteria
Exclusion criteria: Pregnancy or lactation, Endocrine glands problems: adrenal hyperplasia, androgen-secreting tumor, hyperprolactinemia, thyroid dysfunction, diabetes, Cushing's syndrome. History of premature menopause, smoking or history of smoking, significant changes in diet, and people who have taken antibiotics one month before the start of the study. Taking a probiotic supplement. Having any disorder other than PCOS that is associated with excessive androgens and menstrual irregularities, vitamin D sensitivity Having a chronic disease such as autoimmune disease, active liver disease, having a history of heart and kidney diseases, pancreatitis, lung disease and having a diet and any type of additional physical activity such as aerobics and using omega-3 and multivitamins Using drugs that interfere with vitamin D, such as anticonvulsants, rifampin and isoniazid, digoxin, and magnesium hydroxide and aluminum hydroxide antacids. alcohol consumption Allergy to probiotics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of 25 hydroxyvitamin D. Timepoint: The beginning and end of the study. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: The beginning and end of the study. Method of measurement: Scale.;Body composition. Timepoint: The beginning and end of the study. Method of measurement: Bioelectrical Impedance Analysis.;Body Mass Index. Timepoint: The beginning and end of the study. Method of measurement: Bioelectrical Impedance Analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShaghayegh Torabali
Oroumia University of Medical Sciences
Outcome results
None listed